More on AMGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $267.70 |
|
|||
| Open | $267.54 | ||||
| 52 Wk High | $176.85 | ||||
| 52 Wk Low | $133.64 | ||||
| Day High | $267.28 | ||||
| Day Low | $266.30 | ||||
| P/E | 40.19 | ||||
| EPS | $6.64 | ||||
| Volume | 1,704,924 | ||||
- Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
- AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
- INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
- Amgen (AMGN) PT Raised to $280 at Argus
- Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
- Morgan Stanley is adding to its position in Adobe (ADBE), removes Cisco (CSCO) position
- Form 8-K AMGEN INC For: Sep 11
- Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
- Amgen (AMGN) Reports New LUMAKRAS Plus Chemo Data
Entities mentioned with AMGN
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Barron's | View Related Stories »
- Citi | View Related Stories »
- Options | View Related Stories »
- Show More...
